AVXL patent info, straight from anavex IR email ... feel free to dissect
Thank you for your email and interest in Anavex Life Sciences Corp. (Nasdaq: AVXL).
As per its latest annual report, Anavex holds ownership or exclusive rights to three issued U.S. patent and eight U.S. patent applications with various international counterpart applications, all of which relate to drug candidates and methods associated therewith. These include:
Issued US Patents
U.S. 9,180,106 to Vamvakides “Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity.”
U.S. 8,673,931 to Fisher et al. “Bicyclic heterocyclic spiro compounds.”
U.S. 9,034,891 to Fisher et al. “Bicyclic heterocyclic spiro compounds.”
Pending (published) US/PCT patent applications
USSN 13/777,471, to Vamvakides, “Sigma Receptors Ligands With Anti-Apoptotic And/Or Pro-Apoptotic Properties, Over Cellular Mechanisms, Exhibiting Prototypical Cytoprotective And Also Anti-Cancer Activity.”
USSN 13/940352 to Vamvakides et al., “Anavex2-73 And Certain Anticholinesterase Inhibitors Composition And Method For Neuroprotection.”
PCT/US2015/056172 to Missling et al., “A19-144, A2-73 and Certain Anticholinesterase Inhibitor Compositions and Method for Anti-Seizure Therapy.”
Please do not hesitate to contact our office if we can be of further assistance.
On behalf of Anavex Life Sciences Corp.,
Investor Relations
Toll Free (North America): 1 (866) 505-2895
Outside North America: +1 (416) 489 0092
Fax: +1 (416) 352 5239
